본문 바로가기
KERD
논문KCI 등재

Emerging Therapies for Hepatitis C

한광협|안상훈|김도영
거트앤리버 소화기연관학회협의회|2014.09|Gut and Liver|제8권 제5호|pp. 471-479

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

RibavirinHepatitis CDirect acting antiviralPegylated interferon

초록

The combination of pegylated interferon (PEG-IFN) and ribavirin(RBV), the current therapy for hepatitis C virus (HCV)infection, has saved the lives of many HCV-infected patients. Direct-acting antivirals (DAAs) target several sites of HCVnonstructural proteins, resulting in the cessation of viralreplication. The first NS3/4A protease inhibitors consistedof boceprevir and telaprevir, which have shown superior efficacyagainst genotype 1 HCV infection when combined withPEG-IFN/RBV compared with the standard therapy in bothtreatment-naive and -experienced patients. Simeprevir, faldaprevir,and asunaprevir are second-wave, first-generationNS3/4A inhibitors that have already been or will soon be approved. Second-generation protease inhibitors are in clinicaltrials. Daclatasvir is the first approved DAA belonging to theclass of NS5A replication complex inhibitors. The potencyof daclatasvir is very high, and this drug is an importantand essential component of combination regimens for allgenotypes. Sofosbuvir, the first approved NS5B polymeraseinhibitor, is characterized by high potency and genetic barriersto resistance. Sofosbuvir combined with RBV achievedan interferon-free regimen in genotype 2 or 3 patients with areduced treatment duration. It can also be used in combinationwith PEG-IFN/RBV in genotype 1 patients for 12 weeks. DAAs have provided new hope for curing HCV infections witha short treatment duration and acceptable adverse events.

Abstract

The combination of pegylated interferon (PEG-IFN) and ribavirin(RBV), the current therapy for hepatitis C virus (HCV)infection, has saved the lives of many HCV-infected patients. Direct-acting antivirals (DAAs) target several sites of HCVnonstructural proteins, resulting in the cessation of viralreplication. The first NS3/4A protease inhibitors consistedof boceprevir and telaprevir, which have shown superior efficacyagainst genotype 1 HCV infection when combined withPEG-IFN/RBV compared with the standard therapy in bothtreatment-naive and -experienced patients. Simeprevir, faldaprevir,and asunaprevir are second-wave, first-generationNS3/4A inhibitors that have already been or will soon be approved. Second-generation protease inhibitors are in clinicaltrials. Daclatasvir is the first approved DAA belonging to theclass of NS5A replication complex inhibitors. The potencyof daclatasvir is very high, and this drug is an importantand essential component of combination regimens for allgenotypes. Sofosbuvir, the first approved NS5B polymeraseinhibitor, is characterized by high potency and genetic barriersto resistance. Sofosbuvir combined with RBV achievedan interferon-free regimen in genotype 2 or 3 patients with areduced treatment duration. It can also be used in combinationwith PEG-IFN/RBV in genotype 1 patients for 12 weeks. DAAs have provided new hope for curing HCV infections witha short treatment duration and acceptable adverse events.

참고문헌 (55)

  1. Sievert W, "A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt", Liver Int, 31(Suppl 2), pp.61~80 (2011)
  2. Kim do Y, "A nationwide seroepidemiology of hepatitis C virus infection in South Korea", Liver Int, 33, pp.586~594 (2013)
  3. Baatarkhuu O, "Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population-based nationwide study", Liver Int, 28, pp.1389~1395 (2008)
  4. Ascione A, "Natural history of chronic hepatitis C virus infection", Dig Liver Dis, 39(Suppl 1), pp.S4~S7 (2007)
  5. Ly KN, "The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007", Ann Intern Med, 156, pp.271~278 (2012)
  6. George SL, "Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients", Hepatology, 49, pp.729~738 (2009)
  7. Cardoso AC, "Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis", J Hepatol, 52, pp.652~657 (2010)
  8. McHutchison JG, "Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection", N Engl J Med, 361, pp.580~593 (2009)
  9. Backus LI, "Predictors of response of US veterans to treatment for the hepatitis C virus", Hepatology, 46, pp.37~47 (2007)
  10. Scheel TK, "Understanding the hepatitis C virus life cycle paves the way for highly effective therapies", Nat Med, 19, pp.837~849 (2013)
  11. Poenisch M, "New insights into structure and replication of the hepatitis C virus and clinical implications", Semin Liver Dis, 30, pp.333~347 (2010)
  12. Victrelis, "Whitehouse Station" (2011), Merck & Co., Inc
  13. Kwo PY, "Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial", Lancet, 376, pp.705~716 (2010)
  14. Poordad F, "Boceprevir for untreated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1195~1206 (2011)
  15. Bacon BR, "Boceprevir for previously treated chronic HCV genotype 1 infection", N Engl J Med, 364, pp.1207~1217 (2011)
  16. Vierling JM, "Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon", ribavirin, including prior null response, 2014, pp.60, 748~756
  17. Bruno S, "Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study", Hepatology, 45, pp.579~587 (2007)
  18. Morgan TR, "Outcome of sustained virological responders with histologically advanced chronic hepatitis C", Hepatology, 52, pp.833~844 (2010)
  19. Bruno S, "Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis", cirrhosis, 2013, pp.58, 479~487
  20. Poordad F, "Factors that predict response of patients with hepatitis C virus infection to boceprevir", Gastroenterology, 143, pp.608~618 (2012)
  21. Ghany MG, "An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases", Hepatology, 54, pp.1433~1444 (2011)
  22. Jacobson IM, "A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C", J Viral Hepat, 19(Suppl 2), pp.1~26 (2012)
  23. McHutchison JG, "Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection", N Engl J Med, 360, pp.1827~1838 (2009)
  24. Jacobson IM, "Telaprevir for previously untreated chronic hepatitis C virus infection", N Engl J Med, 364, pp.2405~2416 (2011)
  25. McHutchison JG, "Telaprevir for previously treated chronic HCV infection", N Engl J Med, 362, pp.1292~1303 (2010)
  26. Zeuzem S, "Telaprevir for retreatment of HCV infection", N Engl J Med, 364, pp.2417~2428 (2011)
  27. Hézode C, "Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890", J Hepatol, 59, pp.434~441 (2013)
  28. Fried MW, "Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study", Hepatology, 58, pp.1918~1929 (2013)
  29. Jacobson I, "Simeprevir (TMC435) with peginterferon", ribavirin for chronic HCV genotype 1 infection in treatment-naive patients: results from QUEST-1, a phase III trial, 2013, pp.58, S574~
  30. Manns M, "Simeprevir (TMC435) with peginterferon", ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-2, a phase III trial, 2013, pp.58(Suppl 1), S568~
  31. Zeuzem S, "Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial", Gastroenterology, 146, pp.430~441 (2014)
  32. Lawitz E, "Simeprevir (TMC435) with peginterferon", ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a phase III trial, 2013, pp.144(Suppl 1), S151~
  33. Sulkowski MS, "Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic genotype 1 HCV: SILEN-C1 trial", Hepatology, 57, pp.2143~2154 (2013)
  34. Ferenci P, "Faldaprevir plus pegylated interferon alfa-2A and ribavirin in chronic HCV genotype-1 treatment-naive patients: final results from STARTVerso1, a randomized, double blind, placebo-controlled phase III trial", J Hepatol, 58(Suppl 1), pp.S569~ (2013)
  35. Jensen DM, "A pooled analysis of two randomized, double-blind placebo-controlled phase III trials (STARTVerso 1&2) of faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection", Hepatology, 58(Suppl 1), pp.734A~ (2013)
  36. Zeuzem S, "Faldaprevir and deleobuvir for HCV genotype 1 infection", N Engl J Med, 369, pp.630~639 (2013)
  37. Bronowicki JP, "Randomized study of asunaprevir plus pegylated interferon-α and ribavirin for previously untreated genotype 1 chronic hepatitis C", Antivir Ther, 18, pp.885~893 (2013)
  38. Suzuki Y, "Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options", J Hepatol, 58, pp.655~662 (2013)
  39. Lok AS, "Randomized trial of daclatasvir and asunaprevir with or without PegIFN", RBV for hepatitis C virus genotype 1 null responders, 2014, pp.60, 490~499
  40. Everson GT, "Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection", Gastroenterology, 146, pp.420~429 (2014)
  41. Gentile I, "Daclatasvir: the first of a new class of drugs targeted against hepatitis C virus NS5A", Curr Med Chem, 21, pp.1391~1404 (2014)
  42. Suzuki F, "A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection", Antivir Ther (2014)[DOI]
  43. Lee C., "Daclatasvir: potential role in hepatitis C", Drug Des Devel Ther, 7, pp.1223~1233 (2013)
  44. Kowdley KV, "Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1", N Engl J Med, 370, pp.222~232 (2014)
  45. "SovaldiTM (sofosbuvir) tablets, for oral use: US prescribing information" (2013)[URL]
  46. Lawitz E, "Sofosbuvir for previously untreated chronic hepatitis C infection", N Engl J Med, 368, pp.1878~1887 (2013)
  47. Kowdley KV, "Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial", Lancet, 381, pp.2100~2107 (2013)
  48. Jacobson IM, "Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options", N Engl J Med, 368, pp.1867~1877 (2013)
  49. Sulkowski MS, "Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection", N Engl J Med, 370, pp.211~221 (2014)
  50. Zeuzem S, "SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +", - ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of SOUND-C2, 2012, pp.56(Suppl 1), S45~
  51. Gane EJ, "All-oral sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: the ELECTRON study", J Hepatol, 58(Suppl 1), pp.S6~ (2013)
  52. Kowdley KV, "Safety and efficacy of interferon-free regimens of ABT-450", r, ABT-267, ABT-333 +, J Hepatol, pp.2013, 58(Suppl 1)[DOI]
  53. Sulkowski MS, "Complete SVR4 rates in treatment-naive HCV genotype 1a and 1b patients who achieved vRVR with an interferon-free all-oral regimen", Hepatology, 56(Suppl 1), pp.298A~ (2012)
  54. Suzuki Y, "Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options", J Hepatol, 58, pp.655~662 (2013)
  55. Lok AS, "Sustained virologic response in chronic HCV genoptype (GT) 1-infected null responders with combination of daclatasvir (DCV; NS5A inhibitor) and asunaprevir (ASV; NS3 inhibitor) with or without peginterferon alfa-2a", ribavirin (PEG, Hepatology, pp.2012, 56(Suppl 1)[DOI]

관련 논문AI추천

The Therapeutic Approaches for Hepatitis C Virus: Protease Inhibitors and Polymerase InhibitorsPaul Y. Kwo, Rakesh Vinayek거트앤리버 소화기연관학회협의회 · Gut and Liver2011 · 제5권 제4호만성 C형 간염 치료의 최근 발전김태헌, 이준성대한내과학회 · 대한내과학회지2014 · 제86권 제5호Therapy with Direct-Acting Antiviral Agents for Hepatitis C-Related Liver CirrhosisNobuyuki Toshikuni거트앤리버 소화기연관학회협의회 · Gut and Liver2017 · 제11권 제3호Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection양현, 남희철, 송명준, 이해림대한간학회 · Clinical and Molecular Hepatology2016 · 제22권 제2호Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failureAlessio Aghemo, Maria Corina Plaz Torres, Tommaso Lorenzo Parigi대한간학회 · Clinical and Molecular Hepatology2019 · 제25권 제4호Hepatitis C Virus and Antiviral Drug ResistanceKwang-Hyub Han, Sang Hoon Ahn, Seungtaek Kim거트앤리버 소화기연관학회협의회 · Gut and Liver2016 · 제10권 제6호

이 간행물의 다른 논문 (15건)

The Myth and Truth about the Usefulness of Second-Look Endoscopy Following Endoscopic Submucosal Resection김혜강, 정대영pp. 459-461Recent Advances in the Concept and Pathogenesis of IgG4-Related Disease in the Hepato-Bilio-Pancreatic SystemKazushige Uchida, Toshiyuki Mitsuyama, Masahito Yanagawa, Kazuichi Okazakipp. 462-470The Need for Second-Look Endoscopy to Prevent Delayed Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms: A Prospective Randomized Trial정조윤, 양대열, 명대성, 정민우, 주영은, 박형철, 조성범, 김종선, 이완식pp. 480-486RING Finger Proteins Are Involved in the Progression of Barrett Esophagus to Esophageal Adenocarcinoma: A Preliminary StudyWei Qiang Wang, Dian Chun Fang, Xing Wei Wang, Xiao-Yan Zhao, Hong Guo, Wei Weipp. 487-494T-Fastener Migration after Percutaneous Gastropexy for Transgastric Enteral Tube InsertionRyan H. Sydnor, Stacey M. Schriber, Charles Yoon Kimpp. 495-499
원문 보기